Last updated: September 12, 2026
Anthrax Vaccine Adsorbed, Adjuvanted, marketed as Cyfendus, is an Emergent BioSolutions vaccine approved by the FDA in 2023 for post-exposure prophylaxis against Bacillus anthracis in adults ages 18 to 65 when used with antibacterial drugs and when alternatives are unavailable or inappropriate.[1] Its market is defined by U.S. government procurement, national-security stockpiling, and limited institutional demand rather than routine commercial vaccination.
Cyfendus has a protected commercial position through its biologics exclusivity period, regulatory approval, manufacturing complexity, and government purchasing relationships. Its financial trajectory depends more on federal contract awards, stockpile replenishment, and biodefense policy than on patient volume or traditional vaccine-market penetration.
What is Anthrax Vaccine Adsorbed, Adjuvanted?
Anthrax Vaccine Adsorbed, Adjuvanted combines anthrax vaccine adsorbed, or AVA, with the CpG 7909 adjuvant. Emergent developed the product under the designation AV7909 and markets it as Cyfendus.[1]
Cyfendus is distinct from BioThrax, which is also an Emergent product but contains AVA without the CpG 7909 adjuvant.
| Product |
Active platform |
FDA status |
Primary use |
Manufacturer |
| BioThrax |
Anthrax Vaccine Adsorbed |
Licensed |
Pre-exposure prophylaxis and post-exposure prophylaxis under specified conditions |
Emergent BioSolutions |
| Cyfendus |
Anthrax Vaccine Adsorbed, Adjuvanted |
Licensed in 2023 |
Post-exposure prophylaxis with antibacterial drugs |
Emergent BioSolutions |
| Anthrax immune globulin intravenous |
Human anthrax antitoxin |
Licensed |
Treatment adjunct for inhalational anthrax |
Emergent BioSolutions |
| Antibiotics |
Antibacterial drugs |
Multiple approvals |
Treatment and post-exposure prophylaxis |
Multiple companies |
Cyfendus is not a conventional replacement for BioThrax. The products address different regulatory indications and vaccination schedules. Cyfendus is designed for rapid post-exposure use, while BioThrax remains the established product for pre-exposure protection in individuals at occupational or military risk.
What is the FDA regulatory status of Cyfendus?
The FDA approved Cyfendus on June 23, 2023, through the Animal Rule pathway.[1] The efficacy of anthrax vaccines cannot be established through conventional human efficacy trials because deliberate exposure studies would be unethical. The FDA therefore relies on animal efficacy data, pharmacokinetic and immunogenicity evidence, and human safety data.
The approved indication covers adults ages 18 to 65 who have been exposed, or may have been exposed, to Bacillus anthracis and require post-exposure prophylaxis in conjunction with antibacterial drugs.
The product received priority review and was supported by federal biodefense programs. Its commercial use is expected to remain concentrated in:
- Strategic National Stockpile procurement
- Department of Defense requirements
- Civilian emergency-response reserves
- Selected occupational or laboratory-risk populations
- Government-funded preparedness programs
The product does not have a broad retail vaccine market. Routine physician-administered demand is unlikely to become a material revenue driver.
When does Cyfendus lose regulatory exclusivity?
Cyfendus received 12 years of reference-product data exclusivity under the Biologics Price Competition and Innovation Act. The period is generally measured from the first licensure date of the reference biological product, subject to statutory interpretation and regulatory treatment.[2]
For Cyfendus, the practical reference-product exclusivity period is expected to extend into 2035 based on its 2023 approval. That date does not necessarily establish the earliest possible commercial entry of every competing product. Patent claims, regulatory review, manufacturing readiness, product-specific interchangeability issues, and government procurement rules may affect actual competition.
| Milestone |
Date or period |
| AV7909 development |
Before 2023 |
| FDA approval of Cyfendus |
June 23, 2023 |
| Expected 12-year biologics exclusivity horizon |
Approximately June 2035 |
| Main commercial market |
U.S. government and biodefense procurement |
| Conventional generic pathway |
Not available |
| Biosimilar pathway |
Legally possible in principle, commercially difficult |
Cyfendus is a biologic vaccine, so a conventional small-molecule generic application under section 505(j) of the Food, Drug, and Cosmetic Act is not applicable. A competing biologic would require a biosimilar or other biologics-license pathway, depending on the product and regulatory strategy.
What patents protect Anthrax Vaccine Adsorbed, Adjuvanted?
The commercial protection for Cyfendus is likely distributed across composition, adjuvant, formulation, manufacturing, dosing, and use claims rather than a single product patent.
Potential protection categories include:
| Protection category |
Commercial relevance |
| AVA and CpG 7909 composition |
Covers the combination of antigen and adjuvant |
| Adjuvant formulation |
May address concentration, particle characteristics, buffering, or stability |
| Dosing regimen |
Can protect accelerated or post-exposure administration schedules |
| Manufacturing process |
May protect antigen adsorption, mixing, purification, filling, or quality-control steps |
| Stability and storage |
Important for stockpile shelf life and deployment logistics |
| Method of use |
May cover post-exposure prophylaxis with antibiotics |
| Device and presentation |
May cover vial, syringe, packaging, or emergency-use presentation |
There is no conventional Orange Book listing for Cyfendus because the Orange Book primarily catalogs approved small-molecule drug products and associated patents. Biological products are tracked through FDA biologics records and patent databases rather than through the same Orange Book framework used for conventional drugs.[3]
The absence of a conventional Orange Book listing does not mean that Cyfendus lacks patent protection. It means that a potential competitor would need to evaluate issued patents, pending applications, regulatory exclusivity, manufacturing know-how, and trade-secret barriers outside the standard Orange Book Paragraph IV framework.
How strong is the Cyfendus patent estate?
The practical strength of the Cyfendus franchise is greater than a simple patent-count analysis would indicate.
Composition and adjuvant protection
CpG 7909 is an important differentiating component. A competitor could attempt to develop an anthrax vaccine using a different adjuvant, but that approach could require new clinical, immunogenicity, stability, and Animal Rule data. A product using the same antigen-adjuvant architecture would face greater risk of patent overlap and development delay.
Manufacturing protection
Anthrax vaccine manufacturing requires controlled antigen production, adsorption to aluminum-containing adjuvant, sterile filling, validated release testing, and supply-chain controls. Government customers also require consistency, traceability, and surge capacity.
Manufacturing know-how may therefore remain commercially important after patent expiration. Process patents can be designed around, but process changes may require substantial comparability work and regulatory validation.
Regulatory protection
The 12-year biologics exclusivity period is likely more important than any single patent for preventing near-term biosimilar competition. The product also benefits from the limited number of organizations with anthrax-antigen manufacturing infrastructure and prior biodefense contracting experience.
Patent-strength assessment
| Factor |
Assessment |
| Composition protection |
Potentially strong if claims cover the specific antigen-adjuvant combination |
| Method-of-use protection |
Useful but dependent on claim scope and prior art |
| Manufacturing protection |
Strong practical barrier because of process complexity |
| Regulatory exclusivity |
High value through approximately 2035 |
| Biosimilar threat before 2035 |
Low |
| Biosimilar threat after 2035 |
Possible but commercially constrained |
| Small-molecule generic threat |
Not applicable |
Which companies are challenging Cyfendus?
No major public commercial challenge to Cyfendus has been established through a conventional Paragraph IV filing. That outcome is consistent with the product’s biologic status and the small size of the anthrax market.
Potential competition is more likely to arise from:
- Other government-funded vaccine developers
- Military research programs
- Contractors developing next-generation anthrax vaccines
- International anthrax vaccine manufacturers
- Alternative post-exposure products, including antitoxins and antibiotics
The competitive threat is therefore more likely to be programmatic than litigation-driven. A government may sponsor an alternative platform even if the private-market economics do not justify independent development.
What is the Orange Book status of Cyfendus?
Cyfendus does not operate like a conventional Orange Book drug. It is a licensed biologic vaccine, not a small-molecule drug product with a standard Orange Book patent-and-exclusivity listing.
The relevant regulatory records are:
- FDA biologics licensing materials.
- FDA product labeling.
- Public patent databases.
- BPCIA reference-product and biosimilar records.
- Federal procurement records.
- Emergent’s SEC filings and government-contract disclosures.
A prospective competitor would not use a standard Paragraph IV certification as the primary route to challenge Cyfendus. The relevant dispute would more likely involve patent litigation under the BPCIA framework, a biologics-license application strategy, or a contract and procurement challenge.
What patent litigation affects Cyfendus?
There is no widely reported major patent litigation campaign centered on Cyfendus as of the available public record. This is commercially rational. The product’s market is small, government-controlled, and protected by regulatory and manufacturing barriers.
Potential litigation could arise from:
- Claims covering CpG 7909 or related oligonucleotide adjuvants
- Patent ownership disputes involving government-funded research
- Licensing disputes involving adjuvant technology
- Manufacturing-process patents
- Biosimilar applications after the exclusivity period
- Government procurement protests
- Contract-performance or supply disputes
The absence of public litigation does not eliminate legal exposure. A patent review should include Emergent’s patent families, legacy AVA rights, adjuvant-related patents, and rights arising from federal research funding.
How does Cyfendus compare with BioThrax?
Cyfendus and BioThrax share an anthrax-vaccine platform but occupy different commercial and regulatory positions.
| Attribute |
Cyfendus |
BioThrax |
| Antigen platform |
AVA |
AVA |
| CpG 7909 adjuvant |
Yes |
No |
| FDA approval |
2023 |
Earlier license history |
| Principal indication |
Post-exposure prophylaxis |
Pre-exposure and specified post-exposure use |
| Primary buyer |
U.S. government |
U.S. government and defined institutional users |
| Market maturity |
Newer product |
Established stockpile product |
| Revenue visibility |
Dependent on new procurement awards |
Supported by recurring stockpile demand |
| Competitive risk |
Low near term |
Low but exposed to procurement substitution |
| Manufacturing base |
Emergent |
Emergent |
Cyfendus can expand Emergent’s anthrax portfolio, but it also creates product overlap. Government buyers may choose between products based on exposure scenario, dosing requirements, stockpile design, cost, and inventory policy.
What drives the financial trajectory of Cyfendus?
Cyfendus revenue is likely to be lumpy and contract-based. The major drivers are:
Strategic National Stockpile purchases
The Strategic National Stockpile is the most important potential buyer. Stockpile contracts can generate large revenue in discrete periods, followed by years with lower sales. Revenue timing depends on inventory rotation, expiration dates, replenishment schedules, and federal appropriations.
Department of Defense demand
Military demand is driven by force protection and deployment planning. Procurement is not tied to ordinary vaccination rates. A change in threat assessment can affect order volume materially.
Product shelf life
Longer shelf life improves the economics of stockpiling. It reduces waste, extends the period between replenishment cycles, and can make the product more attractive in government tenders.
Contract structure
Government agreements can include base quantities, options, milestone payments, surge provisions, and delivery schedules. Reported contract value should not be treated as annual revenue. Option periods may never be fully exercised, and revenue recognition can occur over multiple years.
Emergent’s balance sheet and portfolio
Cyfendus is part of a broader Emergent biodefense portfolio that includes BioThrax, anthrax immune globulin, smallpox products, and other government-funded countermeasures. Product-level revenue is not always separately disclosed in public filings, limiting precision in standalone valuation.
What is the revenue exposure from Cyfendus?
Cyfendus is strategically important but is unlikely to support a large, diversified commercial revenue stream without substantial federal purchases.
The revenue profile has four characteristics:
- High customer concentration, with U.S. government agencies representing the principal demand source.
- Low recurring retail demand.
- High order volatility because purchases occur through procurement cycles.
- Strong dependence on political and budgetary support for biodefense programs.
A procurement award can have a material effect on annual revenue, while the absence of an award can produce a sharp decline without indicating loss of medical demand.
Investors should separate:
- Contract ceiling value from recognized revenue
- Product sales from government development funding
- Base orders from option orders
- Anthrax franchise revenue from total Emergent revenue
- Cash collections from accounting revenue
Emergent does not provide a complete, consistently reported public revenue series for Cyfendus alone. Standalone revenue estimates based only on total company results carry a high risk of attribution error.[4]
What generic or biosimilar launch risks exist?
The near-term risk of a competing Cyfendus product is low. The most credible entry scenarios are post-2035 and would require a competitor to establish:
- A comparable anthrax antigen supply chain
- An adjuvant platform with suitable immune-response data
- Manufacturing at validated commercial scale
- FDA acceptance under the biologics framework
- Government procurement eligibility
- Sufficient demand to recover development costs
A biosimilar could face an unfavorable return profile because the market is small and concentrated. The competitor would also confront a well-established incumbent with government relationships and manufacturing history.
The more realistic risk is substitution by a different biodefense product rather than a direct biosimilar. New vaccines, antitoxins, or improved antibiotic regimens could reduce the need for the existing product if they offer better protection, simpler dosing, longer shelf life, or lower total procurement cost.
What licensing and partnership issues affect the product?
Cyfendus relies on technology originating from a broader research and biodefense ecosystem. Relevant commercial rights may include:
- CpG adjuvant licensing
- Government-funded research rights
- University or contractor inventions
- Manufacturing licenses
- Technology-transfer agreements
- Federal acquisition terms
Public disclosures do not establish a separate, widely reported third-party commercial licensing transaction that determines Cyfendus’ market access. Emergent’s principal advantage is its existing anthrax manufacturing and government-contracting infrastructure.
What is the geographic market for Cyfendus?
The United States is the principal commercial market. FDA approval does not automatically establish broad international sales. Foreign sales would require country-specific regulatory approvals, procurement decisions, and often government-to-government purchasing arrangements.
Geographic expansion is constrained by:
- Limited civilian anthrax incidence
- National biodefense procurement policies
- Local regulatory requirements
- Export controls
- Government ownership or control of strategic stockpiles
- The availability of domestic anthrax vaccines in certain countries
The product’s commercial value is therefore concentrated in U.S. federal procurement and selected allied-country preparedness programs.
Key Takeaways
- Cyfendus is Anthrax Vaccine Adsorbed combined with CpG 7909 and is marketed by Emergent BioSolutions.
- The FDA approved it in June 2023 for post-exposure prophylaxis in adults ages 18 to 65, used with antibacterial drugs.
- Its market is government-led, with the Strategic National Stockpile and Department of Defense as the principal demand centers.
- Expected biologics exclusivity extends approximately to 2035.
- Conventional generic competition is not applicable; biosimilar competition is legally possible but commercially difficult.
- Cyfendus does not have the standard Orange Book profile of a small-molecule drug.
- No major public Paragraph IV challenge or Cyfendus-centered patent litigation campaign has been established.
- Manufacturing capability, federal procurement history, adjuvant technology, and stockpile contracts are as important as patent claims.
- Revenue is likely to be episodic, contract-driven, and difficult to isolate from Emergent’s broader biodefense portfolio.
- The principal long-term threat is alternative biodefense technology or procurement substitution, not routine generic entry.
FAQs
Is Cyfendus the same as BioThrax?
No. Both use anthrax vaccine adsorbed, but Cyfendus contains the CpG 7909 adjuvant and is approved for post-exposure prophylaxis. BioThrax is the established AVA product used primarily for pre-exposure protection.
Can a company file a generic application for Cyfendus?
No. Cyfendus is a biologic vaccine, so a conventional ANDA under section 505(j) is not the applicable pathway. A competitor would generally need to pursue a biosimilar or another biologics-licensing strategy.
Does Cyfendus have an Orange Book patent listing?
Cyfendus does not have the standard Orange Book status associated with small-molecule drugs. Its regulatory and patent analysis requires review of biologics records, patent databases, exclusivity rules, and federal procurement disclosures.
Why is the anthrax vaccine market financially attractive despite low patient volume?
Government buyers purchase vaccines for emergency reserves rather than routine patient use. Large stockpile orders can produce meaningful revenue even when ordinary clinical demand is minimal.
What could reduce Cyfendus sales before patent or biologics exclusivity expires?
Sales could decline if federal procurement priorities change, stockpile inventories reach target levels, a competing biodefense product is adopted, or government buyers substitute BioThrax or another anthrax countermeasure for the same preparedness requirement.
References
- U.S. Food and Drug Administration. (2023, June 23). FDA approves vaccine for post-exposure prevention of anthrax disease. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Biological product development: 351(k) biosimilar application pathway. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
- Emergent BioSolutions, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov
